Clinical Advances in Hematology and Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Addressing unmet need in the management of patients with ER+/HER2-, ESR1-mutated metastatic breast cancer: clinician's perspective
Clin Adv Hematol Oncol. 2023 Dec;21(12):623-632.ABSTRACTApproximately 70% of breast tumors are ER+ and HER2-. First-line treatment that combines endocrine therapy (AIs, SERMs, and SERDs) with a CDK4/6 inhibitor is the treatment of choice for many patients with ER+/HER2- metastatic breast cancer. However, ESR1 mutations develop in up to 40% of patients-more than 90% of these in response to therapy. The presence of ESR1 mutations is associated with a worse prognosis, including faster progression and poorer survival, underscoring the need for routine testing and the urgency of developing novel therapies that address ESR1-muta...
Source: Clinical Advances in Hematology and Oncology - December 1, 2023 Category: Cancer & Oncology Authors: Hope S Rugo Source Type: research

Novel combination approaches to locoregional and systemic therapy in the management of primary and metastatic liver tumors
Clin Adv Hematol Oncol. 2023 Dec;21(12):633-643.ABSTRACTSeveral pathways and mutations must develop or be in place for the onset of cancer. Therefore, therapies should ideally target as many of these pathways as possible to improve outcomes. Combining several agents has proven to be more effective than the use of monotherapy in the treatment of renal cell carcinoma, hepatocellular carcinoma, and other cancers. Combination therapy can also include locoregional therapies such as ablation and embolization with systemic agents for synergistic effects. This review article discusses the current literature and clinical trials cov...
Source: Clinical Advances in Hematology and Oncology - December 1, 2023 Category: Cancer & Oncology Authors: Michelle Dai Bryan-Clement Y Tiu Millennie Chen Caitlyn Sing Vinay Sharma Juan Pablo Hoyos Riley Scherr Wei Ju Lin Joseph A Breuer Farshid Dayyani David Imagawa Nadine Abi-Jaoudeh Source Type: research

Chemotherapy and immunotherapy in early-stage NSCLC: neoadjuvant vs adjuvant therapy
Clin Adv Hematol Oncol. 2023 Dec;21(12):648-651.NO ABSTRACTPMID:38039058 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 1, 2023 Category: Cancer & Oncology Authors: Heather Wakelee Source Type: research

Update on the CAPTIVATE trial of ibrutinib plus venetoclax
Clin Adv Hematol Oncol. 2023 Dec;21(12):654-657.NO ABSTRACTPMID:38039059 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 1, 2023 Category: Cancer & Oncology Authors: Tanya Siddiqi Source Type: research

The National Cancer Institute's Clinical Trials Innovation Unit
Clin Adv Hematol Oncol. 2023 Dec;21(12):663-665.NO ABSTRACTPMID:38039060 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 1, 2023 Category: Cancer & Oncology Authors: Michael J Morris Sheila Prindiville Source Type: research

EGFR inhibitor rechallenge in metastatic colorectal cancer
Clin Adv Hematol Oncol. 2023 Dec;21(12):670-672.NO ABSTRACTPMID:38039061 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 1, 2023 Category: Cancer & Oncology Authors: Jun Gong Source Type: research

Preventing infectious complications in chronic lymphocytic leukemia
Clin Adv Hematol Oncol. 2023 Dec;21(12):676-677.NO ABSTRACTPMID:38039062 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 1, 2023 Category: Cancer & Oncology Authors: Clare Sun Source Type: research